Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Mera Giler, et al., “Changes in Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States:(2012–2016).,” presented at the In 9th International AIDS society conference on HIV science (pp. 23–26), 2017.
2. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018. https://doi.org/10.1016/j.annepidem.2018.05.003.
3. Golub SA. PrEP Stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7. https://doi.org/10.1007/s11904-018-0385-0.
4. Harkness A, et al. Scaling up and out HIV prevention and behavioral health services to latino sexual minority men in South Florida: multi-level implementation barriers, facilitators, and strategies. AIDS Patient Care STDS. 2021;35(5):167–79. https://doi.org/10.1089/apc.2021.0018.
5. “Volume 28 Number 4| HIV Surveillance | Reports | Resource Library | HIV/AIDS | CDC.” Accessed: Jan. 30, 2024. [Online]. Available: https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-4/index.html